Recent Posts

News, RareDiseases, GenomicsEngland
Congenica named as genomic analysis platform in ‘Impact of the 100,000 Genomes Pilot – Preliminary Report’ in the New England Journal of Medicine
Posted 11th November 2021

Congenica named as genomic analysis platform in ‘Impact of the 100,000 Genomes Pilot – Preliminary Report’ in the New England Journal of Medicine

Read More
Blog , genomics , RareDiseases , GenomicsEngland
100k Genomes Pilot on Rare Disease Diagnosis in Healthcare
Posted 11th November 2021

100k Genomes Pilot on Rare Disease Diagnosis in Healthcare

Read More
1
News , RareDiseases , GenomicsEngland
Congenica named as genomic analysis platform in ‘Impact of the 100,000 Genomes Pilot – Preliminary Report’ in the New England Journal of Medicine
Posted 11th November 2021

Congenica named as genomic analysis platform in ‘Impact of the 100,000 Genomes Pilot – Preliminary Report’ in the New England Journal of Medicine

Read More
Blog , genomics , RareDiseases , GenomicsEngland
100k Genomes Pilot on Rare Disease Diagnosis in Healthcare
Posted November Nov 11th 2021

100k Genomes Pilot on Rare Disease Diagnosis in Healthcare

Read More
1
CE 60px-Conformité_Européenne - WHITE27001 RGB Tick 60x60 Congenica UL® ISO 13485:2016 A28485 HIPAA Compliance

Copyright © 2022 Congenica Ltd. Company number: 8273616 Registered in England and Wales

Congenica is available as a CE Marked IVD clinical decision support platform for clinical diagnostic use for inherited genetic disorders in the UK and EU, Iceland, Lichtenstein, Norway, Switzerland and Turkey. In all other countries, ensuring compliance with relevant local, national and international clinical laboratory regulations is the responsibility of the laboratory.